Novavax Total Revenue vs Property Plant Equipment Analysis
NVAX Stock | USD 14.91 0.12 0.81% |
Novavax financial indicator trend analysis is infinitely more than just investigating Novavax recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novavax is a good investment. Please check the relationship between Novavax Total Revenue and its Property Plant Equipment accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.
Total Revenue vs Property Plant Equipment
Total Revenue vs Property Plant Equipment Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novavax Total Revenue account and Property Plant Equipment. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Novavax's Total Revenue and Property Plant Equipment is 0.91. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Property Plant Equipment in the same time period over historical financial statements of Novavax, assuming nothing else is changed. The correlation between historical values of Novavax's Total Revenue and Property Plant Equipment is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Novavax are associated (or correlated) with its Property Plant Equipment. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant Equipment has no effect on the direction of Total Revenue i.e., Novavax's Total Revenue and Property Plant Equipment go up and down completely randomly.
Correlation Coefficient | 0.91 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Total Revenue
Total revenue comprises all receipts Novavax generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Property Plant Equipment
Most indicators from Novavax's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 442.5 M in 2024, despite the fact that Tax Provision is likely to grow to (1.8 M).
Novavax fundamental ratios Correlations
Click cells to compare fundamentals
Novavax Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novavax fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 173.0M | 1.6B | 2.6B | 2.3B | 1.9B | 1.9B | |
Other Current Liab | 19.9M | (327.6M) | 709.8M | 1.5B | 1.2B | 1.3B | |
Total Current Liabilities | 25.8M | 322.0M | 2.4B | 2.5B | 1.6B | 1.7B | |
Total Stockholder Equity | (186.0M) | 627.2M | (351.7M) | (634.1M) | (716.9M) | (681.1M) | |
Property Plant And Equipment Net | 11.4M | 180.0M | 228.7M | 400.5M | 491.0M | 515.5M | |
Net Debt | 243.1M | (231.4M) | (1.1B) | (787.1M) | (298.3M) | (283.4M) | |
Retained Earnings | (1.4B) | (1.9B) | (3.6B) | (4.3B) | (4.8B) | (4.6B) | |
Accounts Payable | 2.9M | 54.3M | 127.1M | 216.5M | 132.6M | 139.2M | |
Cash | 78.8M | 553.4M | 1.5B | 1.3B | 578.9M | 607.9M | |
Non Current Assets Total | 75.7M | 334.3M | 421.6M | 555.3M | 711.5M | 747.0M | |
Non Currrent Assets Other | 7.5M | 13.2M | 56.7M | 28.5M | 30.3M | 31.8M | |
Cash And Short Term Investments | 78.8M | 711.0M | 1.5B | 1.3B | 578.9M | 607.9M | |
Common Stock Shares Outstanding | 24.1M | 57.6M | 74.4M | 78.2M | 100.8M | 105.8M | |
Liabilities And Stockholders Equity | 173.0M | 1.6B | 2.6B | 2.3B | 1.9B | 1.9B | |
Other Current Assets | 93.9M | 441.8M | 2.1B | 1.7B | 226.0M | 191.7M | |
Other Stockholder Equity | 1.3B | 2.5B | 3.3B | 3.6B | 4.1B | 4.3B | |
Total Liab | 359.0M | 955.3M | 2.9B | 2.9B | 2.6B | 2.7B | |
Property Plant And Equipment Gross | 11.4M | 180.0M | 258.6M | 447.8M | 566.0M | 594.3M | |
Total Current Assets | 97.2M | 1.2B | 2.2B | 1.7B | 1.1B | 1.2B | |
Accumulated Other Comprehensive Income | (12.5M) | 7.0M | (1.4M) | (6.4M) | 2.7M | 2.9M | |
Net Receivables | 7.5M | 262.0M | 455.0M | 82.4M | 297.2M | 312.1M | |
Non Current Liabilities Total | 333.2M | 633.2M | 538.1M | 432.8M | 937.1M | 984.0M | |
Intangible Assets | 6.5M | 5.6M | 5.7M | 4.8M | 4.3M | 4.1M | |
Short Long Term Debt Total | 321.9M | 322.0M | 454.0M | 549.8M | 280.6M | 294.7M | |
Common Stock Total Equity | 3.8M | 324K | 714K | 764K | 878.6K | 1.3M | |
Short Term Debt | 1.3M | 322.0M | 130.5M | 352.1M | 28.1M | 43.9M | |
Common Stock | 324K | 714K | 764K | 868K | 1.4M | 1.3M | |
Long Term Debt | 320.6M | 322.0M | 323.5M | 166.5M | 168.0M | 114.6M | |
Inventory | (83.0M) | (166.7M) | (2.0B) | 36.7M | 41.7M | 43.8M | |
Property Plant Equipment | 11.4M | 180.0M | 228.7M | 400.5M | 460.6M | 483.6M | |
Other Liab | 2.6M | 3.4M | 175.5M | 185.0M | 212.8M | 223.4M | |
Current Deferred Revenue | 1.7M | 273.2M | 1.4B | 370.1M | 241.3M | 140.2M | |
Other Assets | 1.1M | 5.4M | 16.6M | 28.5M | 32.7M | 34.4M | |
Good Will | 51.2M | 135.4M | 131.5M | 126.3M | 127.5M | 133.8M | |
Net Tangible Assets | (242.8M) | 486.1M | (487.9M) | (760.4M) | (684.4M) | (650.1M) | |
Retained Earnings Total Equity | (1.3B) | (1.4B) | (1.9B) | (3.6B) | (3.3B) | (3.1B) | |
Long Term Debt Total | 319.2M | 320.6M | 322.0M | 323.5M | 372.0M | 234.9M | |
Capital Surpluse | 1.1B | 1.3B | 2.5B | 3.4B | 3.9B | 4.0B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Transaction History View history of all your transactions and understand their impact on performance | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.07) | Revenue Per Share 8.726 | Quarterly Revenue Growth 0.159 | Return On Assets (0.16) | Return On Equity (8.98) |
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.